X0609 4 2026-08-07 0001637715 OnKure Therapeutics, Inc. OKUR 0001622769 Manke Isaac false C/O ONKURE THERAPEUTICS, INC. 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 true false false false 0 Stock Option (right to buy) 4.14 2026-08-07 4 A 0 300000 0 A 2036-08-06 Class A Common Stock 300000 300000 D Stock Option (right to buy) 18.20 2026-08-07 4 D 0 15300 D 2034-10-03 Class A Common Stock 15300 0 D Stock Option (right to buy) 4.14 2026-08-07 4 A 0 15300 A 2034-10-03 Class A Common Stock 15300 15300 D 1/4th of the shares subject to the option shall vest on February 24, 2027 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. /s/ Rogan Nunn, by power of attorney 2026-08-11